CancerVax to Webcast Corporate Presentation at Piper Jaffray Health Care Conference.Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Jan. 22, 2004 CancerVax Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CNVX) announced today that President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David F. Hale will present a corporate overview on Tuesday, January 27, 2004 at 10:30 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ) during the Piper Jaffray Health Care Conference. Mr. Hale's presentation will provide an overview of the Company's clinical programs, including its two ongoing Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. with the specific active immunotherapeutic, Canvaxin(TM), for the treatment of advanced-stage melanoma. A live recording of CancerVax's presentation will be available at http://ir.cancervax.com. To access the presentation, click on the link entitled "Event Schedule" on the left side of the screen. The webcast will be available for 30 days. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company's lead product candidate, Canvaxin(TM), is one of a new class of products being developed in the area of specific active immunotherapy active immunotherapy The administration of substances to evoke a protective immune response in the form of specific antibodies. Cf Passive immunotherapy, Vaccine. , also known as therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine . Canvaxin(TM) is currently being studied in two international Phase 3 clinical trials for the treatment of patients with Stage III or IV, or advanced-stage, melanoma. The Company is also finalizing the design of a Phase 2 clinical trial phase 2 clinical trial Phase 2 study. See Phase study. in patients with Stage III colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. . In addition to Canvaxin(TM), the Company has a number of product candidates in research and preclinical development, including a specific active immunotherapy product candidate for lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. and several monoclonal antibodies and peptides that target other cancers. The Company also plans to identify and develop new product candidates based on our proprietary specific active immunotherapy platform, our anti-angiogenesis technology platform, and other technologies. CancerVax's corporate headquarters and research and development facility is located in Carlsbad, California and our biologics manufacturing facility is located in Los Angeles, California. CancerVax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; and other risks detailed in CancerVax's Securities and Exchange Commission filings, including CancerVax's Prospectus on Form 424 (b)(4) filed on October 30, 2003 and Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the fiscal quarter ended September 30, 2003. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. CancerVax(R) is a registered trademark of CancerVax Corporation. Canvaxin(TM) is a trademark of CancerVax Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion